4. MODEL EARLY STAGE INVESTIGATIONS
THIS COURSE DOES NOT TEACH…
• BASIC SCIENCE
• BASIC ENTREPRENEURSHIP
• GENERAL STARTUP, PATENTS +VC FUNDING
• HOWTO COMMERCIALIZETECH FROMTHE LABS
• FDA REGS + REIMBURSEMENT
• PHARMA DEVELOPMENT, CLINICALTRIALS PROCESS
IMPOSSIBLETO COMPRESSTHIS INTO A CLASS…
WE TEACH A DIFFERENT PHILOSOPHY…
5. ACTIVE LEARNING LAB
WITH EARLY CLASS SUCCESSES >$90 MILLION RAISED
FOR WHICH HCV DESERVES NO CREDIT!
8. CARE RE-DESIGN + CO-CREATION
PARTNERSHIP WITH
MGH HEALTHTRANSFORMATION LAB
TAKE MIT TEAMS DEEP INTO
DISEASETREATMENT WORKFLOWS
HOSPITAL OPERATIONS
www.cocreate.hctransformationlab.org
13. HEALTHCARE IS MORE COMPLEX
WHO BUYS?
WHO BENEFITS?
WHO PRESCRIBES?
CLASS JOURNEY: NAVIGATE COMPLEXITY
WHO COMPETES?
14.
15. VALUE
TIMECRITICAL MILESTONES
Acquisition/IPO Exit
Reimbursement
Published clinical results
Market Introduction
Salesforce hired
Europe & Japan distribution
FDA Approval
Manufacturing ramp
Human pivotal study
Corporate partnership
First human data
First Hiccup & Danger of Momentum Loss
CEO hired
Pilot manufacturing
Patent grant
First FDA meeting
Regulatory opinions
Money raised & team hired
Animal testing
Clinician feedback
Patent disclosure
Prototype/Reduction to Practice
Market Analysis
Idea
TRADITIONAL MEDICALVENTURES
LONG DEVELOPMENT PROCESS
16. “… MVP is that product which has
just those features (and no more) that
allows you to ship a product that
resonates with early adopters; some of whom will
pay you money or give you feedback.”
“The MVP is often an ad on Google.
Or a PowerPoint slide. Or a dialog box. Or a landing page.
You can often build it in a day or a week.”
— Eric Ries
MINIMUMVIABLE PRODUCT
PILLPACK’S 24 HR PROTOTYPE
18. VALUE
TIMECRITICAL MILESTONES
Acquisition/IPO Exit
Reimbursement
Published clinical results
Market Introduction
Salesforce hired
Europe & Japan distribution
FDA Approval
Manufacturing ramp
Human pivotal study
Corporate partnership
First human data
First Hiccup & Danger of Momentum Loss
CEO hired
Pilot manufacturing
Patent grant
First FDA meeting
Regulatory opinions
Money raised & team hired
Animal testing
Clinician feedback
Patent disclosure
Prototype/Reduction to Practice
Market Analysis
Idea
FRONT-LOAD USER FEEDBACK
BEFORE FUNDING + LAUNCHING A 10YEAR JOURNEY
FOCUS MVP
PRIORITIZE RISKS
FASTER LAUNCH, ROI
19. DE-RISKINGVENTURES
HOW BESTVC INVESTORS PRIORITIZE RISK
VALUE
TIME
Market Adoption Risk
Reimbursement + Consumer Drivers
Physician & Patient Adoption
Distribution
Regulatory Risk
Safety & Efficacy
Management Risk
Technology Risk
PRIORITIZE
UP FRONT
20. TECHNIQUES +TECH FOR
SCALING MEDICINE
•DE-SKILL COMPLEX DIAGNOSIS +TREATMENT
•CREATE NEW EXPERIENCE + PROCESS
•CREATE NEW PLACE or NEW SERVICE
•FIND NEW PROVIDER + EXTRA CAPACITY
•PATIENT ENGAGEMENT + SELF-SERVICE
•NEWTECH ENABLES SCALABILITY + ACCESS
… START WITH A GIANT PAINFUL PROBLEM
29. HOW HIGH IS THE TIGHTROPE FORYOU?
ENTREPRENEUR MINDSET
NOT FOR EVERYONE
APPRECIATE CHALLENGES
VENTURE CAPITAL ANALYSIS
EVALUATE HEALTHCARE VENTURES